Bank of New York Mellon’s Standard BioTools LAB Stock Holding History

Bank of New York Mellon’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$74.3K	Sell	90,282 -676,671	-88%	-$639K	﹤0.01%	4217
2026 Q1	$705K	Sell	766,953 -26,646	-3%	-$32.3K	﹤0.01%	3421
2025 Q4	$1.02M	Sell	793,599 -4,539	-0.6%	-$6.1K	﹤0.01%	3227
2025 Q3	$1.04M	Buy	798,138 +20,401	+3%	+$26.7K	﹤0.01%	3192
2025 Q2	$933K	Buy	777,737 +44,868	+6%	+$49.7K	﹤0.01%	3163
2025 Q1	$791K	Sell	732,869 -7,321	-1%	-$10.3K	﹤0.01%	3190
2024 Q4	$1.3M	Sell	740,190 -15,278	-2%	-$28.5K	﹤0.01%	2991
2024 Q3	$1.46M	Sell	755,468 -225,515	-23%	-$442K	﹤0.01%	2918
2024 Q2	$1.74M	Buy	980,983 +893,383	+1,020%	+$2.18M	﹤0.01%	2877
2024 Q1	$237K	Sell	87,600 -22,521	-20%	-$54.4K	﹤0.01%	3882
2023 Q4	$243K	Buy	110,121 +12,420	+13%	+$26.5K	﹤0.01%	3886
2023 Q3	$283K	Sell	97,701 -2,062	-2%	-$5.39K	﹤0.01%	3821
2023 Q2	$193K	Sell	99,763 -19,642	-16%	-$38.8K	﹤0.01%	3988
2023 Q1	$233K	Hold	119,405	–	–	﹤0.01%	3857
2022 Q4	$140K	Buy	119,405 +16,344	+16%	+$20.1K	﹤0.01%	4069
2022 Q3	$113K	Buy	103,061 +52,417	+104%	+$79.2K	﹤0.01%	4171
2022 Q2	$81K	Sell	50,644 -229,542	-82%	-$568K	﹤0.01%	4269
2022 Q1	$1.01M	Sell	280,186 -6,815	-2%	-$23.5K	﹤0.01%	3313
2021 Q4	$1.13M	Buy	287,001 +4,957	+2%	+$23.2K	﹤0.01%	3317
2021 Q3	$1.86M	Buy	282,044 +22,822	+9%	+$150K	﹤0.01%	3026
2021 Q2	$1.6M	Sell	259,222 -50,070	-16%	-$268K	﹤0.01%	3145
2021 Q1	$1.4M	Sell	309,292 -154,868	-33%	-$851K	﹤0.01%	3140
2020 Q4	$2.79M	Buy	464,160 +45,617	+11%	+$300K	﹤0.01%	2651
2020 Q3	$3.11M	Sell	418,543 -76,714	-15%	-$530K	﹤0.01%	2441
2020 Q2	$1.99M	Sell	495,257 -53,221	-10%	-$185K	﹤0.01%	2682
2020 Q1	$1.39M	Buy	548,478 +26,651	+5%	+$87.6K	﹤0.01%	2747
2019 Q4	$1.82M	Sell	521,827 -11,220	-2%	-$39.5K	﹤0.01%	2868
2019 Q3	$2.47M	Sell	533,047 -38,261	-7%	-$301K	﹤0.01%	2641
2019 Q2	$7.04M	Buy	571,308 +22,898	+4%	+$292K	﹤0.01%	2172
2019 Q1	$7.29M	Buy	548,410 +89,729	+20%	+$946K	﹤0.01%	2147
2018 Q4	$3.95M	Buy	458,681 +29,310	+7%	+$228K	﹤0.01%	2429
2018 Q3	$3.22M	Sell	429,371 -4,140	-1%	-$29.4K	﹤0.01%	2606
2018 Q2	$2.58M	Buy	433,511 +35,091	+9%	+$200K	﹤0.01%	2718
2018 Q1	$2.33M	Buy	398,420 +14,708	+4%	+$96.6K	﹤0.01%	2723
2017 Q4	$2.26M	Buy	383,712 +13,285	+4%	+$72.7K	﹤0.01%	2778
2017 Q3	$1.87M	Buy	370,427 +152,588	+70%	+$641K	﹤0.01%	2882
2017 Q2	$880K	Buy	217,839 +11,261	+5%	+$53.4K	﹤0.01%	3318
2017 Q1	$1.18M	Buy	206,578 +35,176	+21%	+$223K	﹤0.01%	3151
2016 Q4	$1.25M	Sell	171,402 -20,181	-11%	-$127K	﹤0.01%	3130
2016 Q3	$1.53M	Buy	191,583 +5,609	+3%	+$51.5K	﹤0.01%	2930
2016 Q2	$1.68M	Buy	185,974 +5,419	+3%	+$50.9K	﹤0.01%	2821
2016 Q1	$1.46M	Buy	180,555 +12,304	+7%	+$88.7K	﹤0.01%	2837
2015 Q4	$1.82M	Buy	168,251 +10,977	+7%	+$108K	﹤0.01%	2773
2015 Q3	$1.28M	Sell	157,274 -4,189	-3%	-$65.9K	﹤0.01%	3029
2015 Q2	$3.91M	Sell	161,463 -27,893	-15%	-$880K	﹤0.01%	2518
2015 Q1	$7.97M	Buy	189,356 +12,874	+7%	+$509K	﹤0.01%	2058
2014 Q4	$5.95M	Buy	176,482 +26,459	+18%	+$749K	﹤0.01%	2227
2014 Q3	$3.68M	Buy	150,023 +6,012	+4%	+$169K	﹤0.01%	2493
2014 Q2	$4.23M	Sell	144,011 -9,008	-6%	-$289K	﹤0.01%	2416
2014 Q1	$6.74M	Sell	153,019 -20,976	-12%	-$923K	﹤0.01%	2144
2013 Q4	$6.66M	Buy	173,995 +30,421	+21%	+$896K	﹤0.01%	2123
2013 Q3	$3.15M	Buy	143,574 +17,184	+14%	+$338K	﹤0.01%	2541
2013 Q2	$2.21M	Buy	+126,390	New	+$2.22M	﹤0.01%	2729

Other funds holding LAB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

MAM

Marquette Asset Management Minneapolis, Minnesota $779M AUM 23.4% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Bank of New York Mellon's LAB Position: Q2 2026 in Review

Bank of New York Mellon reduced its Standard BioTools (LAB) stake by 88% in Q2 2026, selling an estimated $639K and leaving 90,282 shares worth $74.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4217.

Bank of New York Mellon first reported a position in LAB in Q2 2013 and has held it in 53 quarters since. The position peaked at $7.97M in Q1 2015. 45 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

Bank of New York Mellon held 90,282 shares of Standard BioTools worth $74.3K as of Q2 2026.
Bank of New York Mellon sold 676,671 Standard BioTools shares in Q2 2026, an estimated $639K.
Standard BioTools made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #4217 holding.
Bank of New York Mellon first reported a position in Standard BioTools in Q2 2013 and has held it in 53 quarters since.
Bank of New York Mellon's Standard BioTools position peaked at $7.97M in Q1 2015.
45 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.